Medtronic Names VP of Medical Affairs, Coronary and Peripheral

Martin Rothman has served as director of cardiac research and development at London Chest Hospital.

By: Editor

NULL

Martin Rothman has been hired as vice president of medical affairs for Medtronic Inc.’s coronary and peripheral vascular business in Santa Rosa, Calif., according to the Minneapolis, Minn.-based firm.

Rothman has 37 years of clinical practice in the United Kingdom as an interventional cardiologist, including 27 years at the London Chest Hospital (Barts and the London NHS Trust) in London, England, where he served for more than a decade as director of cardiac research and development. He has made significant contributions to clinical research, training and education and medical technology innovation in cardiovascular medicine, according to the medical device giant.

“Prof. Rothman stands out as a pioneer and leader in interventional cardiology,” said Sean Salmon, vice president and general manager of the Coronary and Peripheral division.

According to the firm, Rothman is a regular presenter at medical meetings and has authored peer-reviewed journal articles and has conducted scores of interventional cardiology-related trials.

Additionally, Rothman has participated as an investigator in studies of Medtronic’s Endeavor drug-eluting coronary stents and has led cardiac stem cell research for heart failure treatment. He also established the largest heart attack center in Europe, Medtronic said.

During his tenure at the London Chest Hospital, Rothman developed a training program for interventional cardiology, the treatment of patients with heart disease through minimally invasive techniques such as angioplasty and transcatheter valves. He also has developed live case demonstrations, which enable clinicians to learn through observation and interaction with the physicians performing the procedures.

In 1985, Rothman created his first start-up company, which developed intravascular ultrasound technology to enable clinicians to see inside their patients’ arteries. He sold the company in May 2000.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters